Artificial intelligence has moved from a background tool into a visible presence in American political advertising and its arrival is…
A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer…
Men make up just 5% of people getting genetic tests for inherited cancer risks despite dying from cancer at higher rates than…
Recent research shows how chemotherapy and immunotherapy can complement each other when used together. Within this evolving scientific landscape, LIXTE…
Researchers have found that people under 50 who develop colorectal cancer have unusually rigid colon tissue that helps tumors grow, offering the first clear…
The U.S. military has confirmed that AI systems are actively involved in its ongoing operations against Iran, an admission that has added significant fuel to…
LIXTE Biotechnology Holdings and Liora Technologies recently joined forces to soon offer a real fight against cancer. LIXTE develops LB-100,…
LIXTE recently expanded its ovarian clear cell cancer trial in partnership with MD Anderson and GSK The company operates at…
New research has uncovered a shared biological weakness running across three distinct pediatric brain cancers, a finding that opens a realistic path…
LIXTE Biotechnology Holdings and the company’s subsidiary, Liora Technologies, both develop products that aim to improve outcomes for cancer patients…